MX2010012019A - Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. - Google Patents
Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.Info
- Publication number
- MX2010012019A MX2010012019A MX2010012019A MX2010012019A MX2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonist
- pharmaceutical product
- muscarinic receptor
- adrenoceptor agonist
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is a β2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0808710A GB0808710D0 (en) | 2008-05-13 | 2008-05-13 | New combination 296 |
GB0900563A GB0900563D0 (en) | 2009-01-14 | 2009-01-14 | New combination |
PCT/SE2009/050525 WO2009139708A1 (en) | 2008-05-13 | 2009-05-12 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010012019A true MX2010012019A (en) | 2011-03-04 |
Family
ID=41318921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010012019A MX2010012019A (en) | 2008-05-13 | 2009-05-12 | Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110190309A1 (en) |
EP (1) | EP2315589A4 (en) |
JP (1) | JP2011520877A (en) |
KR (1) | KR20110010725A (en) |
CN (2) | CN102908624A (en) |
AU (1) | AU2009247021B2 (en) |
BR (1) | BRPI0912657A2 (en) |
CA (1) | CA2723909A1 (en) |
MX (1) | MX2010012019A (en) |
RU (1) | RU2010147881A (en) |
WO (1) | WO2009139708A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
CN102089304A (en) | 2008-05-13 | 2011-06-08 | 阿斯利康(瑞典)有限公司 | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
KR101845257B1 (en) | 2011-02-07 | 2018-04-04 | 삼성전자주식회사 | image sensor |
JP2011195593A (en) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | Quinuclidine derivative as muscarinic m3 receptor antagonist |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL62140C (en) * | 1942-12-16 | |||
GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GR1001529B (en) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters |
US6223485B1 (en) * | 1996-06-07 | 2001-05-01 | Herman Miller, Inc. | Wall panel system |
CA2261692A1 (en) * | 1996-07-29 | 1998-02-05 | Rolf Johansson | Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation |
US6613795B2 (en) * | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
EP1383730A2 (en) * | 2001-04-03 | 2004-01-28 | Aryx Therapeutics | Anticholinergic compounds and methods of use |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
AR044134A1 (en) * | 2003-05-02 | 2005-08-24 | Novartis Ag | DERIVATIVES OF QUINUCLIDINE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS. |
GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
WO2008059239A1 (en) * | 2006-11-14 | 2008-05-22 | Astrazeneca Ab | Novel compounds 514 |
TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
GB0702457D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
CN102089304A (en) * | 2008-05-13 | 2011-06-08 | 阿斯利康(瑞典)有限公司 | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
JP2011195593A (en) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | Quinuclidine derivative as muscarinic m3 receptor antagonist |
-
2009
- 2009-05-12 CN CN2012104520326A patent/CN102908624A/en active Pending
- 2009-05-12 KR KR1020107025392A patent/KR20110010725A/en not_active Application Discontinuation
- 2009-05-12 EP EP09746868.0A patent/EP2315589A4/en not_active Withdrawn
- 2009-05-12 JP JP2011509442A patent/JP2011520877A/en active Pending
- 2009-05-12 MX MX2010012019A patent/MX2010012019A/en active IP Right Grant
- 2009-05-12 CA CA2723909A patent/CA2723909A1/en not_active Abandoned
- 2009-05-12 AU AU2009247021A patent/AU2009247021B2/en not_active Ceased
- 2009-05-12 US US12/992,226 patent/US20110190309A1/en not_active Abandoned
- 2009-05-12 WO PCT/SE2009/050525 patent/WO2009139708A1/en active Application Filing
- 2009-05-12 CN CN200980127403XA patent/CN102088976B/en not_active Expired - Fee Related
- 2009-05-12 BR BRPI0912657A patent/BRPI0912657A2/en not_active IP Right Cessation
- 2009-05-12 RU RU2010147881/15A patent/RU2010147881A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2009247021B2 (en) | 2012-06-07 |
US20110190309A1 (en) | 2011-08-04 |
EP2315589A1 (en) | 2011-05-04 |
JP2011520877A (en) | 2011-07-21 |
CN102088976A (en) | 2011-06-08 |
EP2315589A4 (en) | 2013-09-11 |
RU2010147881A (en) | 2012-06-20 |
CN102088976B (en) | 2012-12-26 |
AU2009247021A1 (en) | 2009-11-19 |
KR20110010725A (en) | 2011-02-07 |
CN102908624A (en) | 2013-02-06 |
BRPI0912657A2 (en) | 2016-01-26 |
CA2723909A1 (en) | 2009-11-19 |
WO2009139708A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008363A (en) | Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. | |
IL193762A (en) | Compounds useful in inhibiting dgat1-related disorders, pharmaceutical compositions comprising them and use thereof in preparation of medicaments | |
WO2007106181A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
MY178634A (en) | Topical formulation for a jak inhibitor | |
IL233677A (en) | Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments | |
IL228017A0 (en) | Substituted quinazolinone derivative, pharmaceutical composition comprising same and use thereof for preparation of a medicament | |
WO2012080729A3 (en) | Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies | |
MX2020012868A (en) | Methods and compositions for sleep disorders and other disorders. | |
WO2007120270A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
WO2007120284A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
HK1166983A1 (en) | Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith | |
WO2009050136A3 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
UA92670C2 (en) | Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon | |
HK1114013A1 (en) | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of repiratory diseases | |
IL211842A (en) | Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesis | |
MX2013007622A (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. | |
GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
UA93709C2 (en) | 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions | |
WO2007114855A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
WO2008026156A3 (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
IL200822A (en) | (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol compound, compositions comprising it and use thereof as medicaments and in the manufacture of medicaments for the treatment or prophylaxis of diseases mediated by some protein kinases | |
MX2010012019A (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. | |
EP2323656A4 (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |